Place of Recent Approvals in Parkinson Disease Management

EP: 1.Off Fluctuations in Parkinson Disease

EP: 2.Adjusting and Changing Treatment Regimens in Parkinson Disease

EP: 3.Recognition of Off Episodes in Parkinson Disease

EP: 4.Conversations About Off Time In Patients With Parkinson Disease

EP: 5.Advanced Treatment Options in Parkinson Disease

EP: 6.Adjunctive Treatments and Apomorphine for Treatment of Parkinson Disease

EP: 7.Continuous Subcutaneous Apomorphine Infusion (CSAI) and TOLEDO Study in Parkinson Disease

EP: 8.CSAI and INFUS-ON Study for Treatment of Parkinson Disease

EP: 9.Continuous Subcutaneous Infusion Systems for Parkinson Disease and Patient Selection Criteria

EP: 10.Place of Continuous Subcutaneous Infusion Systems in Parkinson Disease Management

EP: 11.Clinical Experience With CSAI for Parkinson Disease

Now Viewing

EP: 12.Place of Recent Approvals in Parkinson Disease Management

EP: 13.Patient Conversation and Adoption of CSAI in Clinical Practice

EP: 14.Clinical Nurse Educators, Dosing Titrations to Manage Parkinson Disease

Video content above is prompted by the following:

Place of New Approvals in Parkinson Disease Management

• Expanding options for personalized treatment approaches
• Filling treatment gap between conventional oral therapy and surgical interventions
• Greater flexibility in addressing individual symptom patterns
• Potential for earlier intervention with advanced therapies
• Complementary mechanisms allowing for targeted symptom management
• Options for patients ineligible for certain treatments (eg, deep brain stimulation)
• Need for comparative effectiveness studies to guide selection
• Cost-effectiveness considerations affecting accessibility
• Potential to delay disease progression through improved symptom control
• Opportunity to address previously undertreated population of patients